產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-SCGB3A2抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-SCGB3A2抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-SCGB3A2
Cat. Number:
Anti-SCGB3A2抗體KL-17282R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Uteroglobin-related protein 1 is a 93-amino acid secretory protein that is mainly expressed in lung Clara-like epithelial cells, Anti-SCGB3A2抗體with low levels of expression in the thyroid. The homodimeric UGRP1 may play an anti-inflammatory role in lung inflammation, though the mechanism is still unknown. A macrophage scavenger receptor with collagenous structure (MARCO) acts as a receptor for UGRP1 and may be involved in pathogen clearance in the lung. UGRP1 has a binding site for bacterial lipopolysaccharide (LPS). It is downregulated in antigen-induced inflamed airways, such as allergic asthma, but is upregulated in cystic fibrosis, and interleukin-9 and interleukin-5 modulate UGRP1 expression. UGRP1 may be a therapeutic candidate for treating various sources of lung inflammation
Also known as:
LU103; Pneumo secretory protein 1; Anti-SCGB3A2抗體PnSP-1; PNSP1; Secretoglobin family 3A member 2; UGRP1; Uteroglobin-related protein 1.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Pig, Horse, .
●
Immunogen: KLH conjugatedAnti-SCGB3A2抗體 synthetic peptide derived from human SCGB3A2.
●
Predicted Molecular Weight: 8kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-SCGB3A2抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
